LYRA is expected to report earnings to fall 58.69% to -30 cents per share on November 05
Q3'24
Est.
$-0.31
Q2'24
Missed
by $0.41
Q1'24
Missed
by $0.09
Q4'23
Beat
by $0.13
Q3'23
Beat
by $0.05
The last earnings report on August 14 showed earnings per share of -74 cents, missing the estimate of -33 cents. With 154.35K shares outstanding, the current market capitalization sits at 17.39M.
a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases